the companies confirmed a higher efficacy rate of 95 per cent. The vaccine has been tested on 43,500 people in six countries and no safety concerns have been raised.It has been shown to produce both an antibody and T-cell response in the body.Ugur Sahin, co-founder of BioNTech, said the data shows a high rate of protection against Covid-19 can be achieved “very fast” after the first dose.The UK has secured 40 million doses in total of the vaccine, with 10 million due in the country by the end of the year provided the jab is approved.However people will need two doses, meaning not enough vaccine has been secured for the entire UK population.The vaccine needs to be kept at an ultra-low temperature, between minus 70C and minus 80C, until a few.